Across TCGA pan-cancer cohorts, GM2A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GM2A data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher GM2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GM2A expression acts as an unfavorable survival marker.

LIHC, LUAD, and UCS are the cancer types where GM2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.010	0.784	<.001	12	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	9	view →
UCS	DFS	Median	All	0.126	0.523	.009	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: GM2A tumor-vs-normal RNA expression · all GM2A data types